IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response

Association analysis of class II cytokine and receptor genes in vitiligo patients

“…Earlier investigations have yielded genetic associations with various immune-related diseases from this region: multiple sclerosis [35], systemic sclerosis [36], graft-versus-host disease [37], systemic lupus erythematosus [38], and asthma [39]. Several allelic associations were found.…”

Cytokines Disregulation in Birds and Mammals Infected by Avian Influenza Virus

“…Respon interferon tipe I memerlukan reseptor kompleks yaitu Interferon α Receptor 1 (IFNAR1) dan Interferon α Receptor 2 (IFNAR2) (Leyva et al 2005), melalui aktivasi IFN tipe I melalui Janus kinase (JAK) 1 dan Tyk2 tirosin kinase. Janus kinase 1 dan Tyk2 kinase mengaktifkan beberapa kaskade sinyal pada respon IFN tipe I (de Weerd et al 2007).…”

Translation towards personalized medicine in Multiple Sclerosis

“…Most of the published pharmacogenetics studies in MS employed a candidate gene approach, based on the presumed mechanism of action (MOA) of the drug, such as IFNRA1 and IFNRA2 encoding subunits of the receptor for type I interferons, and on its known metabolic pathways within the body, known as ADME-adsorption, distribution, metabolism and excretion [56,57]. Recently, with the advent of affordable genome-wide approaches, it became possible to screen for response related genetic factors using hypothesis free approaches.…”

“…Studies that benefit from a clinical trial set-up could also include MRI measures to follow disease activity [59]. Among the pharmacogenetics of IFN-b studies published by 5 different research teams, 5 different response measures are used, varying by length of follow-up, inclusion of MRI data, stringency of definition, and whether or not they exclude an intermediate phenotype group [53,56,57,[60][61][62][63][64]. Applying consensus criteria for response may allow sharing of genetic data across studies to exclude disease progression related genetic effects.…”